Genscript Biotech Corporation (HKG: 1548)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 23.25B |
| Revenue (ttm) | 7.88B |
| Net Income (ttm) | -1.38B |
| Shares Out | 2.13B |
| EPS (ttm) | -0.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,311,970 |
| Open | 11.00 |
| Previous Close | 11.00 |
| Day's Range | 10.78 - 11.42 |
| 52-Week Range | 7.43 - 24.50 |
| Beta | 1.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 8, 2024 |
About Genscript Biotech
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, in... [Read more]
Financial Performance
In 2023, Genscript Biotech's revenue was $839.53 million, an increase of 34.17% compared to the previous year's $625.70 million. Losses were -$95.48 million, -57.91% less than in 2022.
Financial numbers in USD Financial StatementsNews
GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia
PISCATAWAY, N.J. , Nov. 10, 2024 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript"), a global leader in life sciences services and products, has announced the establishment of new operations ...
GenScript Biotech Corporation (GNNSF) Q2 2024 Earnings Call Transcript
GenScript Biotech Reports First Half 2024 Results
Strong Revenue Growth and Strategic Advances Across Key Segments, Enhances Commitment to ESG and Sustainable Development Impressive Financial Growth: The group reported a 43.5% increase in revenue, d...
GenScript Biotech Corporation Launches FLASH Gene Service: The Fastest and Most Affordable Gene Synthesis Solution on the Market
PISCATAWAY, N.J. , June 18, 2024 /PRNewswire/ -- GenScript Biotech Corporation, renowned for its relentless innovation in synthetic biology and industry-leading gene synthesis services, is excited to ...
GenScript Biotech Shares Drop After U.S. Lawmakers Scrutinize Chinese Ties
Shares of GenScript Biotech plunged in Hong Kong amid concerns that the company could face U.S. scrutiny due to alleged ties with the Chinese government.
US lawmakers ask FBI for briefing on GenScript Biotech's links to China
The U.S. House of Representatives committee on China has asked the FBI and the intelligence community for a briefing on GenScript Biotechnology Co and three subsidiaries to determine if the Chinese Co...
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications
GenScript continues to build on its fast and dependable in vitro transcription RNA synthesis service, offering a new self-amplifying RNA format that enhances the potency and efficacy of vaccines, immu...
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing
SAN FRANCISCO--(BUSINESS WIRE)-- #manufacturing--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Co...
GenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint
PISCATAWAY, N.J., April 24, 2024 /PRNewswire/ -- Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 ...
GenScript Biotech officially joins SBTi to fulfill its sustainability commitment
PISCATAWAY, N.J. , April 15, 2024 /PRNewswire/ -- On April 15, GenScript Biotech Corporation ("GenScript"), a world's leading technology and service provider of life science R&D and manufacture, annou...
GenScript Biotech Receives EcoVadis Bronze Medal for Outstanding Sustainability Performance
PISCATAWAY, N.J. , March 26, 2024 /PRNewswire/ -- GenScript, a global leader in life science research and application services, is excited to announce that it has been awarded the Bronze Medal by the ...
GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%
R&D Innovation to Lead the Future, Deepening Customer Value Creation Sustained High Revenue Growth: GenScript Group's five-year CAGR stands at an impressive 30%, with a strong global operation and sta...
GenScript Biotech Corporation (GNNSF) Q4 2023 Earnings Call Transcript
GenScript Biotech Corporation (OTCPK:GNNSF) Q4 2023 Results Conference Call March 10, 2024 7:15 PM ET Company Participants Sherry Shao - Rotating CEO Shiniu Wei - CFO Li Chen - ProBio, CEO Patrick Liu...
San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry
SAN FRANCISCO , Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus to San Francisco. The J.P. Morgan Healthcare Conference has bee...
GenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT Industry
NANJING, China , Jan. 4, 2024 /PRNewswire/ -- On January 10, 2024, the GenScript Biotech Global Forum is set to inaugurate with grandeur during the 42nd J.P. Morgan Healthcare Conference in San Franci...
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
NANJING, China , Dec. 24, 2023 /PRNewswire/ -- The innovative development of biopharmaceuticals has ushered in a new era for disease treatment, bringing unprecedented hope to countless patients. Howev...
CRISPR Continuous to Innovate! Exploring the Future of Cell & Gene Therapy, Industry Leaders Converge at the 2024 GenScript Biotech Global Forum
NANJING, China , Dec. 7, 2023 /PRNewswire/ -- The rapid advancement of technology has propelled the field of life sciences into unprecedented growth, constantly expanding our understanding and imagina...
GenScript Biotech Corporation (GNNSF) Q2 2023 Earnings Call Transcript
GenScript Biotech Corporation (OTCPK:GNNSF) Q2 2023 Earnings Conference Call August 20, 2023 7:30 PM ET Company Participants Duan Pengfei - IR Director Robin Meng - Chair of the Board Sherry Shao - Ro...
GenScript Biotech and T-MAXIMUM Biotech Form Strategic Alliance on cGMP sgRNA
GenScript's cGMP sgRNA reagent services enabled FDA-certified orphan drug designation (ODD) for T-MAXIMUM Biotech's MT207 CAR-T cell therapy PISCATAWAY, N.J. and NANJING, China , Aug. 9, 2023 /PRNewsw...
Genscript Biotech Reports 2022 Annual Results*
Non-Cell Therapy Achieved 31.4% Adjusted Net Profit Growth Cell Therapy Business Revenue Surged By 70% Revenue of the Group for the year ended December 31, 2022 was approximately US$625.7 million, rep...
Genscript Biotech Corporation (GNNSF) Q2 2022 Earnings Call Transcript
Genscript Biotech Corporation (OTCPK:GNNSF) Q2 2022 Earnings Conference Call August 31, 2022 6:00 PM ET Company Participants Shiniu Wei - Chief Financial Officer Robin Meng - Chairman of the Board Pat...
GenScript Biotech Expands to the United Kingdom with New Offices and Logistics Center
OXFORD, England--(BUSINESS WIRE)--GenScript Biotech Corp. expands operations in the United Kingdom with new offices and a fully functional logistics center in Oxford.
Hong Kong-Listed Chinese Biotech Stocks Slide on U.S. Sanction Fears
The declines come after the Financial Times reported that the U.S. Commerce Department on Thursday is expected to place some Chinese companies involved in biotechnology on its entity list, which is de...
GenScript Biotech Reports First Half 2021 Results
In the first half of 2021, the Group reported a revenue of approximately USD 229.6 million, a 38.0% YoY increase, and a gross profit of USD 138.6 million, achieving a 28.1% YoY growth. All four of the...
Genscript Biotech Reports 2021 Interim Financial Results
Strong Momentum across All Business Segments, particularly in Gene & Cell Therapy CDMO Continue to accelerate R&D investment to capture Future Growth Revenue of the Group for the six months ended June...